Global Women’s Health Drugs Market to 2024 - Influx of New Products Including Orilissa, Relugolix and Bremelanotide to Diversify Landscape and Drive Growth

1 Table of Contents

1 Table of Contents 4

• 1.1 List of Tables 7
• 1.2 List of Figures 8

2 Introduction 11

• 2.1 Therapy Area Overview 11
  • 2.1.1 Endometriosis 12
  • 2.1.2 Polycystic Ovarin Syndrome 12
  • 2.1.3 Cervical Intraepithelial Neoplasia 12
  • 2.1.4 Menopausal Disorders 12
  • 2.1.5 Infertility 13
• 2.2 Symptoms 13
  • 2.2.1 Endometriosis 13
  • 2.2.2 Polycystic Ovarian Syndrome 13
  • 2.2.3 Cervical Intraepithelial Neoplasia 14
  • 2.2.4 Menopausal Disorders 14
  • 2.2.5 Infertility 14
• 2.3 Diagnosis 14
  • 2.3.1 Endometriosis 14
  • 2.3.2 Polycystic Ovarian Syndrome 15
  • 2.3.3 Cervical Intraepithelial Neoplasia 16
  • 2.3.4 Menopausal Disorders 17
  • 2.3.5 Infertility 17
• 2.4 Etiology and Epidemiology 17
  • 2.4.1 Endometriosis 18
  • 2.4.2 Polycystic Ovarian Syndrome 19
  • 2.4.3 Cervical Intraepithelial Neoplasia 20
  • 2.4.4 Menopause 21
  • 2.4.5 Infertility 21
• 2.5 Pathophysiology 22
  • 2.5.1 Endometriosis 22
  • 2.5.2 Polycystic Ovarian Syndrome 23
  • 2.5.3 Cervical Intraepithelial Neoplasia 24
• 2.6 Co-morbidities and Complications 24
  • 2.6.1 Endometriosis 24
  • 2.6.2 Polycystic Ovarian Syndrome 25
  • 2.6.3 Cervical Intraepithelial Neoplasia 26
  • 2.6.4 Menopause and Menopausal Disorders 26
  • 2.6.5 Infertility 27
• 2.7 Treatment 27
  • 2.7.1 Treatment Options 27

3 Key Marketed Products 33

• 3.1 Overview 33
• 3.2 Premarin family (conjugated estrogens) - Pfizer 33
• 3.3 Lupron/Lupron Depot (leuprolide acetate SR) - AbbVie 35
• 3.4 Gonal-F (follitropin alfa) - Merck KGaA 36
• 3.5 Mirena (levonorgestrel) - Bayer 38
• 3.6 Celebrex (celecoxib) - Pfizer 39
• 3.7 Implanon/Nexplanon (etonogestrel) - Merck & Co. 40
• 3.8 Yasmin/Yaz (drospirenone and ethinylestradiol) - Bayer 42
• 3.9 Nuvaring (ethinylestradiol and etonogestrel) - Merck & Co 43
• 3.10 Gardasil - Merck and Co 44
• 3.11 Esmya (ulipristal acetate) - Gedoen Richter/Allergan 46
• 3.12 Orilissa (elagolix sodium) - AbbVie 48

4 Pipeline Landscape Assessment 50

• 4.1 Overview 50
• 4.2 Pipeline Development Landscape 51
• 4.3 Molecular Targets in the Pipeline 54
• 4.4 Clinical Trials Landscape 56
  • 4.4.1 Clinical Trial Failure Rates 57
  • 4.4.2 Clinical Trial Duration 61
  • 4.4.3 Clinical Trial Size 65
  • 4.4.4 Cumulative Clinical Trial Size 69
• 4.5 Assessment of Key Pipeline Products 72
  • 4.5.1 Relugolix - Takeda Pharmaceutical Co. Ltd 72
  • 4.5.2 Bremelanotide - AMAG Pharmaceuticals Inc 74
  • 4.5.3 SAGE-217 - Sage Therapeutics Inc. 75
  • 4.5.4 Fezolinetant - Ogeda SA 76
  • 4.5.5 Zulresso - Sage Therapeutics 77
  • 4.5.6 Bizalimogene Ralaplasmid + Mavilimogene Ralaplasmid - Inovio Pharmaceuticals Inc 78
  • 4.5.7 Retosiban - GlaxoSmithKline 79

5 Multi-scenario Market Forecast to 2024 81

• 5.1 Overall Market Size 81
• 5.2 Generic Penetration 85
• 5.3 Revenue Forecast by Molecular Target Class 85
  • 5.3.1 G Protein-Coupled Receptor 85
  • 5.3.2 Nuclear Receptor 87
  • 5.3.3 Pathogen 88
  • 5.3.4 Ion Channels/Transporter 89

6 Company Analysis and Positioning 90

• 6.1 Revenue and Market Share Analysis by Company 92
  • 6.1.1 Bayer AG - Company to Remain a Market Leader within Women’s Health 97
  • 6.1.2 AbbVie Inc - Orilissa to Reach Blockbuster Status, Boosting Company’s Market Share 98
  • 6.1.3 Allergan - Revenue Gains From Fibristal, Lo Loestrin Fe and Liletta to Offset Losses from Minastrin 24 Fe and Estrace 99
  • 6.1.4 Merck & Co. - Company to Remain a Key Player Due to Growth of Gardasil/Gardasil 9 100
  • 6.1.5 GlaxoSmithKline - Cervarix and Retosiban to Drive Strong Growth 102
  • 6.1.6 Pfizer - How will patent expiration affect revenues for women’s health market? 103
  • 6.1.7 TherapeuticsMD - Women’s Health Specialist to Gain Considerable Market Share by 2024 104
• 6.2 Company Landscape 105
• 6.3 Marketed and Pipeline Portfolio Analysis 105

7 Strategic Consolidations 108

• 7.1 Licensing Deals 108
  • 7.1.1 Deals by Region, Value and Year 108
  • 7.1.2 Deals by Key Indication 110
  • 7.1.3 Deals by Stage of Development and Value 111
  • 7.1.4 Deals by Molecule Type, Molecular Target and Value 112
  • 7.1.5 Licensing Deals with Disclosed Values 113
• 7.2 Co-development Deals 115
  • 7.2.1 Deals by Region, Value and Year 115
  • 7.2.2 Deals by Key Indication 116
  • 7.2.3 Deals by Stage of Development and Value 117
  • 7.2.4 Deals by Molecule Type, Molecular Target and Value 118
  • 7.2.5 Co-development Deals with Disclosed Values 119

8 Appendix 120

• 8.1 References 120
• 8.2 Abbreivations 127
• 8.3 List of All Pipeline Products 128
• 8.4 Disease List 138
• 8.5 Methodology 138
  • 8.5.1 Coverage 138
  • 8.5.2 Secondary Research 139
  • 8.5.3 Market Size and Revenue Forecasts 139
  • 8.5.4 Pipeline Analysis 139
  • 8.5.5 Competitive Landscape 140
• 8.6 Contact Us 140